NAT2 polymorphism and lung cancer risk: A meta-analysis

被引:22
作者
Cui, Dan [1 ,2 ]
Wang, Zhanwei [3 ]
Zhao, Erjiang [1 ,2 ]
Ma, Jie [4 ]
Lu, Weiquan [1 ]
机构
[1] Henan Tumor Inst, Dept Epidemiol, Zhengzhou 450003, Peoples R China
[2] Zhengzhou Univ, Coll Publ Hlth, Dept Epidemiol & Biostat, Zhengzhou 450001, Peoples R China
[3] Univ Hawaii, Ctr Canc, Thorac Oncol Program, Honolulu, HI 96813 USA
[4] Henan Tumor Hosp, Dept Pathol, Zhengzhou 450003, Peoples R China
关键词
NAT2; Polymorphism; Lung cancer; Meta-analysis; GENETIC POLYMORPHISMS; ACETYLATOR GENOTYPE; N-ACETYLTRANSFERASE; XENOBIOTIC METABOLISM; MOLECULAR-GENETICS; SUSCEPTIBILITY; N-ACETYLTRANSFERASE-2; SMOKING; CARCINOGENESIS; POPULATION;
D O I
10.1016/j.lungcan.2010.12.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
N-acetyltransferase 2 (NAT2) gene encodes a key enzyme involved in the metabolism of xenobiotics and whose polymorphisms have been related to individual susceptibility to several malignancies. Although many epidemiological studies have explored the association between NAT2 genetic polymorphism and lung cancer risk, the results remain controversial. In order to assess the overall relationship between NAT2 polymorphism and lung cancer risk, we performed a meta-analysis including 3945 lung cancer cases and 6085 controls from 19 published studies which were selected from 29 articles identified by a search of PubMed up to 1st June 2010. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association. No significant association was found in overall analysis (OR = 1.02, 95% CI = 0.90-1.16, P = 0.01 for heterogeneity) and in subgroup analyses by ethnicity, sex, histological type, smoking status and study design. In conclusion, this meta-analysis found little evidence of an association between the NAT2 polymorphism and the risk of lung cancer. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:153 / 157
页数:5
相关论文
共 31 条
[1]   'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility [J].
Belogubova, EV ;
Kuligina, ES ;
Togo, AV ;
Karpova, MB ;
Ulibina, JM ;
Shutkin, VA ;
Hanson, KP ;
Popowski, K ;
Mosyagin, I ;
Cascorbi, I ;
Hirvonen, A ;
Imyanitov, EN .
CANCER LETTERS, 2005, 221 (02) :177-183
[2]   N-acetyltransferase 2 ( NAT2) gene polymorphisms in colon and lung cancer patients [J].
Borlak, Juergen ;
Reamon-Buettner, Stella Marie .
BMC MEDICAL GENETICS, 2006, 7
[3]   N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk [J].
Bouchardy, C ;
Mitrunen, K ;
Wikman, H ;
Husgafvel-Pursiainen, K ;
Dayer, P ;
Benhamou, S ;
Hirvonen, A .
PHARMACOGENETICS, 1998, 8 (04) :291-298
[4]   CANCER GENES - SINGLE AND SUSCEPTIBILITY - EXPOSING THE DIFFERENCE [J].
CAPORASO, N ;
GOLDSTEIN, A .
PHARMACOGENETICS, 1995, 5 (02) :59-63
[5]  
Cascorbi I, 1996, CANCER RES, V56, P3961
[6]   Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China [J].
Chen, Han-chun ;
Cao, Yan-fei ;
Hu, Wei-xin ;
Liu, Xin-fa ;
Liu, Qing-xia ;
Zhang, Ji ;
Liu, Jia .
DISEASE MARKERS, 2006, 22 (03) :141-152
[7]   NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan [J].
Chiou, HL ;
Wu, MF ;
Chien, WP ;
Cheng, YW ;
Wong, RH ;
Cheng, CY ;
Lin, TS ;
Lee, H .
CANCER LETTERS, 2005, 223 (01) :93-101
[8]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[9]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634
[10]  
Habalová V, 2005, NEOPLASMA, V52, P364